Abstract
Non-tuberculous mycobacteria (NTM) infection is becoming increasingly prevalent in people with cystic fibrosis (pwCF) and is difficult to treat due to resistance to many antibiotics. Furthermore, infections caused by Mycobacterium abscessus complex (MAC) are more likely to result in a decline in lung function in pwCF than other NTM species. Oral rifampicin is used in multidrug treatment regimens for NTM infections but its use is associated with development of systemic side-effects. The aim of this study was to determine the activity of liposomal loaded rifampicin against mycobacterium abscessus complex clinical respiratory isolates.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
